| P/E (FY) | 5.1 | Sales (TTM) | $18.8M |
| Earnings (TTM) | -$38.9M | ROE | −67.12% |
| Net Margin | −264.44% | ROIC | −304.86% |
| Debt / Equity | 0.07 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $263.4M | Trading Days | 2394 |
| 52W High | 8.95 |
| 52W Low | 3.76 |
| % Off High | −18.99% |
| YTD | −7.88% | 1Y | 27.19% |
| 3Y | −39.18% | 5Y | −51.51% |
| 10Y | −26.77% | Since incept. (ann.) | −3.81% |
US 76% · CA 19% · DE 5%
| Ann. Volatility (1Y) | 72.78% | Ann. Volatility (3Y) | 63.59% |
| Sharpe (1Y) | 0.71 | Sharpe (3Y) | 0.04 |
| Max Drawdown (1Y) | −41.50% | Max Drawdown (3Y) | −68.74% |
| Beta (3Y, vs SPY) | 1.33 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| TMCI | TREACE MEDICAL CONCEPTS, INC. | $264.7M | — |
| TLSI | TriSalus Life Sciences, Inc. | $265.9M | — |
| OSUR | ORASURE TECHNOLOGIES INC | $276.8M | — |
| SGHT | Sight Sciences, Inc. | $288.4M | — |
| PSTV | PLUS THERAPEUTICS, INC. | $292.5M | — |
| OBIO | Orchestra BioMed Holdings, Inc. | $231.1M | — |
| UTMD | UTAH MEDICAL PRODUCTS INC | $225.9M | 20.4 |
| EMBC | Embecta Corp. | $213.0M | 2.2 |
| CARL | CARLSMED, INC. | $334.6M | — |
| ANIK | Anika Therapeutics, Inc. | $201.6M | — |
| INFU | InfuSystem Holdings, Inc | $200.2M |
| 32.0 |
| MOBI | Mobia Medical, Inc. | $370.1M | — |
